Ossopan Bone Health Support Comprehensive Bone Support* Clinical Applications

»» Supports Bone Metabolism* »» Supports Bone Strength* »» Provides Micronutrients for Utilization in Bone Production and Structure* Female Health

Ossopan is a well-researched, standardized extract from one of the world’s safest premium sources of bone—free-range New Zealand cattle. Ossopan contains microcrystalline hydroxyapatite concentrate (MCHC), a complex crystalline compound containing , , bioactive growth factors, type I collagen, amino acids, glycosaminoglycans, and a broad range of essential trace elements that naturally comprise healthy bone.*

Ossopan 1100™ delivers 1100 mg of MCHC per capsule to optimally support bone strength and structure. Ossopan MD™ delivers 500 mg

of MCHC per capsule along with additional calcium and Male Health ® ™ in the form of highly absorbable Albion minerals. Vitamin D, in the Ossopan MD is available in 120 & 240 capsules form of cholecalciferol, supports intestinal calcium absorption and Ossopan 1100™ is available in 120 capsules homeostasis in the body and completes the comprehensiveness of Discussion this bone-support formula.* More than 20 years of scientific research have given the name integrity, and healthy bone metabolism.[9,10] A randomized, controlled Ossopan worldwide recognition as a source of microcrystalline study indicated that the addition of Ossopan to exogenously hydroxyapatite concentrate (MCHC). Numerous published studies administered hormones provided statistically significant support support the safety, tolerability, and bone health-related effectiveness (4.7%, P<0.1) to vertebral bone mass.[10] Another study of 60 subjects of MCHC supplementation.[1,2] Studies suggest that the bioavailability suggested that bone mass was maintained while on Ossopan.*[11] of calcium from MCHC supplements may be as good as or better than the bioavailability of calcium from supplements.[3,4] Ossopan is high-quality MCHC from New Zealand. The World Organization XYMOGEN utilizes standardized, safe, bovine-sourced MCHC from New for Animal Health (the OIE) has classified New Zealand as a “negligible Zealand, a country with stringent standards. Its production features a BSE risk country,” the most favorable official classification a country can proprietary technique that preserves the bioactive contents of bone. be given.[12] Ossopan is manufactured under proprietary processes that This process creates a naturally balanced formula because whole meet FDA, USDA, and EU regulatory requirements. Gentle processing bone extract provides all of the nutrients found in healthy bone.* is used to retain the delicate protein matrix and organic factors. X-ray-diffraction analysis confirms the microcrystalline structure. The Unlike other calcium supplements on the market, Ossopan consists MCHC is assayed for hydroxyproline content. The collagen content of collagenous and non-collagenous proteins and peptides. These is greater than 22% with the majority being type l, the predominant compounds include insulin-like growth factors I and II (IGF-I, IGF-II), collagen occurring in bone. Frequent heavy metal assays assure purity. transforming growth factor beta (TGF-beta), and osteocalcin, factors that stimulate alkaline phosphatase activity and support metabolism in human Ossopan 1100™ delivers 1100 mg of Ossopan per capsule. Ossopan bone cells.[5] Removal of the protein fraction appears to reduce the positive MD™ delivers 500 mg of Ossopan per capsule along with vitamin effects of the formula, highlighting the importance of its presence.*[6] D, magnesium, and additional calcium. Vitamin D is provided as cholecalciferol, which stimulates intestinal calcium absorption and A study suggested that the occurrence of positive and statistically helps support calcium and phosphorus homeostasis in the body. significant changes in forearm bone integrity were the result of daily Calcium is provided as MCHC and DimaCal® dicalcium malate, and supplementation with 3000 mg of microcrystalline hydroxyapatite.[7] magnesium is provided as Albion dimagnesium malate and TRAACS® Earlier studies compared Ossopan to other forms of calcium with regard to magnesium bisglycinate chelate. The buffering malate forms of the support of normal bone turnover and bone integrity. In one calcium and magnesium do not react with stomach acid and are 20-month, double-blind study, women were given 1400 mg of elemental less likely than carbonates to cause discomfort and acid rebound.*[13] calcium (equivalent to approximately 5000 mg MCHC) as either or Ossopan. At the end of the study, the presence of bone integrity was statistically significant in the Ossopan group.*[8]

Clinical trials suggested that Ossopan supplementation was well- tolerated and yielded a positive outcome for dental status, bone

*These statements have not been evaluated by the Food and Drug Administration. XYMOGEN® Exclusive Professional Formulas This product is not intended to diagnose, treat, cure, or prevent any disease. 800-647-6100 | www.xymogen.com Male Health Female Health Bone Health Support © XYMOGEN Laboratories, Inc. 6,706,904. coveredbyUSpatent Malates Albion, DimaCal, and TRAACS areregisteredtrademarksof Albion (GMOs), artificialcolors, sweeteners, artificial orartificial preservatives. peanuts, treenuts, egg, ingredientsderivedfromgenetically modifiedorganisms DOES NOT CONTAIN: STORAGE: if tampersealisdamaged. should discusspotentialinteractionswiththeirhealthcarepractitioner. Donotuse Consult yourhealthcarepractitionerpriortouse. Individualstakingmedication healthcare practitioner. DIRECTIONS: Inc. pending. 6,706,904andpatents coveredbyUSpatent Malates Albion, DimaCal, and TRAACS areregisteredtrademarksof Albion Laboratories, STORAGE: organisms (GMOs), artificialcolors, sweeteners, artificial orartificialpreservatives. shellfish, peanuts, treenuts, egg, ingredientsderivedfromgeneticallymodified DOES NOT CONTAIN: if tampersealisdamaged. should discusspotentialinteractionswiththeirhealthcarepractitioner. Donotuse Consult yourhealthcarepractitionerpriortouse. Individualstakingmedication your healthcarepractitioner. DIRECTIONS: † cellulose, vegetablemagnesiumstearate,andsilica. Other Ingredients: ** DailyValue notestablished. Hydroxyapatite(asMCHC Microcrystalline MCHC Phosphorus (asMCHC Calcium (asMCHC Size:2Capsules Serving Ossopan 1100 Microcrystalline HydroxyapatiteConcentrate. Microcrystalline † triglyceride oil,vegetablemagnesiumstearate,andsilica. Other Ingredients: ** DailyValue notestablished. Hydroxyapatite(asMCHC Microcrystalline MCHC Magnesium (asAlbion Phosphorus (asMCHC Calcium (asMCHC Vitamin D3(cholecalciferol) Size:2Capsules Serving Ossopan MD Microcrystalline HydroxyapatiteConcentrate Microcrystalline † † Keepclosed inacool, placeoutofreachchildren. dry Keeptightlyclosed inacool, placeoutofreachchildren. dry Take withmeals, twocapsules twicedaily, orasdirectedbyyour Take uptotwotimesdaily, onetotwocapsules orasdirectedby ™ HPMC (capsule), vegetable stearic acid, medium-chain triglycerides, microcrystalline HPMC(capsule),vegetablestearicacid,medium-chaintriglycerides,microcrystalline † ) † ™ SupplementFacts andDimaCal SupplementFacts HPMC (capsule), microcrystalline cellulose,vegetablestearicacid, medium-chain HPMC(capsule),microcrystalline † ® ) † ) di-magnesiummalate) Wheat, gluten, yeast, soy, products, dairy fish, shellfish, Wheat, gluten, corn, yeast, soy, products, dairy fish, ® di-calciummalate)

† ) † )

*These statements havenot been evaluatedby the FoodandDrug Administration. This product is notintendedtodiagnose, treat, cure, orprevent any disease. Amount PerServing Amount PerServing All XYMOGEN 198 mg 550 mg 600 mg 100 mg 400 mg 1.32 g 100 IU 90 mg 2.2 g ® 1 g FormulasMeetorExceed cGMPQualityStandards. %Daily Value %Daily Value 25% 40% 25% 20% 55% 9% ** ** ** ** 9. 8. 7. 6. 5. 4. 3. 2. 1. References 13. 12. 11. 10.

[PMID: 2176437] Ossopan[inBulgarian].preparation Khadzhiev A, RachevE, M, Katsarova etal. The resultsofaclinical trialofthe females. inosteoporotic compoundandcalciumcarbonate of ossein-hydroxyapatite Rüegsegger P, Keller A, DambacherMA. effects Comparisonofthetreatment 32. [PMID: 17358094] compound.with anossein-hydroxyapatite osteoporosis: four-year ofacohortpostmenopausalwomentreated follow-up Fernández-Pareja A, Hernández-BlancoE, Pérez-Maceda JM, etal. Preventionof 1986;10(4):241-50. [PMID: 3022988] compound (‘Ossopan’)onthehealingofabonedefect. Annefeld M, R, Caviezel SchachtE, etal. The influenceofossein-hydroxyapatite ossein-mineral-compound. Stepan JJ, MohanS, JenningsJC, etal. factorsin ofgrowth Quantitation 6287835] cirrhosis. biliary with primary ofcorticalbonethinninginpostmenopausalwomen intreatment gluconate Epstein O, Kato Y, DickR, etal. Vitamin D, hydroxyapatite, andcalcium 3026039] French]. and oseine-mineralcomplex: byconventionalanalyses[in anevaluation Buclin T, Jacquet AF, BurckhardtP. Intestinalabsorptionofcalciumgluconate hepatitis. withchronicactive patients in preventionofbonelosscorticosteroid-treated Stellon A, Davies A, Webb A, compound etal. hydroxyapatite Microcrystalline therapy. compound (‘Ossopan’)inthepreventionofosteoporosisduetocorticosteroid Pines A, H, Raafat Lynn AH, etal. hydroxyapatite Clinicaltrialofmicrocrystalline download?start=40. Accessed May9, 2014. Notes Malic acidcanbetherightligandforcertainapplications. official-disease-status/bse/list-of-bse-risk-status/. AccessedMay9, 2014. for Animal Health Web site. http://www.oie.int/animal-health-in-the-world/ ofMembers. Status Bovine SpongiformEncephalopathy OIE-World Organization trial. compounds.loss withossein-hydroxyapatite Resultsofatwo-year, prospective Castelo-Branco C, Pons F, Vicente JJ, etal. Preventingpostmenopausalbone 10202741] hormone replacementtherapy. compounds forpreventingpostmenopausalboneloss. Coadjuvantusewith Castelo-Branco C, MartínezdeOsabaMJ, Pons F, etal. Ossein-hydroxyapatite J ReprodMed. . 2003;12(2).April http://www.albionhumannutrition.com/research-notes/ Curr MedResOpin. Schweiz MedWochenschr. Osteoporos Int. Postgrad MedJ. Additional referencesavailable uponrequest 1999Jul;44(7):601-5. [PMID: 10442322] 1995 Jan;5(1):30-4. [PMID: 7703621] LifeSci. 1985Sep;61(719):791-6. [PMID: 2997764] 1984;8(10):734-42. [PMID: 6373153] Am JClinNutr. J ReprodMed. Akush Ginekol 1991;49(13):PL79-84. [PMID: 1653384] 1986Dec13;116(50):1780-3. [PMID: Clin DrugInvestig. 1982Sep;36(3):426-30. [PMID: 1999 Mar;44(3):241-6. [PMID: ( Sofiia Curr MedResOpin. Albion ). 1990;29(4):85-7. 2007;27(4):227- ® Research Rev. 05/13/15 (RV) DRS-111